News

Intravacc announces formation of Scientific Advisory Board Bilthoven, the Netherlands, 23 February 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced the formation of a Scientific Advisory Board (“SAB”), chaired by Intravacc’s Chief Scientific…

Intravacc neemt moderne pilot productiefaciliteit in gebruik en start concept-design van multifunctionele vaccinfabriek Bilthoven, the Netherlands, 19 februari 2021 – Intravacc, wereldwijd vooraanstaand op het gebied van translationeel onderzoek naar en de ontwikkeling van vaccins, maakt bekend dat haar nieuwe moderne…

• Pilotfabriek geschikt voor productie van vaccins in klinische fase I & II onderzoek
• Consortium werkt plan uit voor nieuwe multifunctionele vaccinfabriek
• Uitgebreide omgevingsvergunningen maken snelle realisatie mogelijk

Dutch Intravacc starts concept design for multifunctional, high-capacity vaccine plant for national requirement New state-of-the-art pilot vaccine production facility ready for use   Bilthoven, the Netherlands, 19 February 2021 – Intravacc, a world leader in translational research and development of…

• New pilot plant for production of vaccine candidates in clinical phase I & II research
• Consortium starts concept design for new multifunctional vaccine factory that can produce enough vaccines for the Netherlands during pandemic
• Extensive environmental permits already in place will enable rapid construction

Intravacc’s Sabin Inactivated Polio vaccine (sIPV), outlicensed to LG Chem, receives WHO prequalification Bilthoven, the Netherlands, 21 January 2021 – Intravacc, a world leader in translational research and development of vaccines, today announces the WHO prequalification for the Sabin-IPV (sIPV)…

• sIPV development is part of Intravacc’s contribution to the eradication of polio
• LG Chem is the first to receive WHO prequalification for the sIPV vaccine
• LG Chem signed an $80 million contract with UNICEF to supply polio vaccine starting early 2021

Intravacc announces completion of formulation and manufacturing process development of PRV-101 vaccine candidate for Provention Bio Bilthoven, the Netherlands, 19 January 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced that a candidate polyvalent…

• Potentially the first preventive vaccine for coxsackievirus B, a risk factor associated with type 1 diabetes and celiac disease
• First dosing of PRV-101 in the PROVENT Phase I clinical trial started in January 2021

Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms Bilthoven and Maastricht, the Netherlands, 6 January 2021 – Intravacc, a world leader in translational research and development of vaccines, and Cristal Therapeutics,  a technology leader in enabling…

• First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2
• Evaluation of Cristal’s CliCr® and Intravacc’s OMV technology

Intravacc appoints three Supervisory Board members Bilthoven, the Netherlands, 4 January 2021 – Intravacc, a world leader in translational research and development of vaccines, announces the appointment of three members in its Supervisory Board. As of January 1, 2021, Intravacc…

• Appointment of Nico Oudendijk (Chair), Bruno Bruins and Karin Dorrepaal
• Intravacc has become public shareholding company as per January 1, 2021

Dutch vaccine developer Intravacc becomes public shareholding company effective 1st January 2021 Bilthoven, The Netherlands, 22 December 2020 –  Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing infectious diseases vaccines,…

• Dutch State will become sole shareholder
• Jan Groen will continue as Chief Executive Officer

Intravacc publishes positive phase I Shigella conjugate vaccine data Bilthoven, The Netherlands, 16 November 2020 –  Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing viral and bacterial vaccines, today announced…

• High medical need for Shigella vaccine
• Over 250 million infections worldwide annually
• Vaccine was well tolerated and induced a significant increase in functional antibodies
• Data published in prestigious journal The Lancet Infectious Diseases

Intravacc appoints Prof. Dr. Virgil Schijns as Chief Scientific Officer Bilthoven, The Netherlands, 5 November 2020 – Intravacc, a global leading contract development and manufacturing organization of viral and bacterial vaccines, today announced the appointment of Prof. Dr. Virgil Schijns,…

Intravacc 2.0 Bilthoven, The Netherlands, 5 October 2020 – After many months of hard work and dedication by our team at Intravacc together with our branding and website agencies, we are pleased to announce the launch of Intravacc 2.0! Our…

• New website and branding
• Matches Intravacc’s aspiration to become a leading vaccine CDMO
• We welcome your feedback on our new website

Intravacc Receives US NIH/NIAID Contract to Develop Enterovirus D68 Vaccine Bilthoven, The Netherlands, 8 September, 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has been awarded a contract…

• Growing concerns about global spread of this respiratory enterovirus
• Vaccine to protect children from Acute Flaccid Myelitis
• Development of inactivated EV D68 vaccine, through to Phase I clinical testing

Intravacc and Therapyx jointly develop the world’s first prophylactic gonorrhea vaccine Bilthoven, The Netherlands, 25 August 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, has partnered with American, Buffalo, NY, based Therapyx,…

• Gonorrhea is the second most common bacterial infectious disease worldwide
• Vaccine based on IL12 in combination with intravacc’s gonorrhea OMV targeting mucosal immunization
• Induce an adaptive immune response for long term protection against the gonorrhea bacteria
• Mucosal vaccine platforms offer a broader perspective also for respiratory virus vaccines, such as Covid-19 and influenza

Intravacc’s candidate RSV vaccine demonstrates safety in phase I trial Bilthoven, The Netherlands, 18 August 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced the publication in the medical journal Vaccine,…

• High unmet need for effective pediatric RSV vaccine
• Continued frequent hospitalization of infected infants and risk to elderly
• Partner orientation for further development of this RSV candidate vaccine

Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine BILTHOVEN, Netherlands and BASEL, Switzerland, 29 July, 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, and Celonic Group, a premium biopharmaceutical…

• Combining Intravacc’s OMV-delivery platform with Covid-19 Spike proteins
• Preclinical studies to start shortly for candidate selection and inhouse pilot scale GMP production

Intravacc and Leiden University developed an animal replacement method for vaccines Bilthoven, The Netherlands, 23 July 2020 – Dutch, Bilthoven based, Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced the publication of…

• Need for alternatives to animal testing in quality control of vaccines
• Inactivation of vaccines can be traced without using laboratory animals
• Findings published in medical journal Scientific Reports

Intravacc to in-license CimCure’s iBoost technology, expanding its vaccine platform portfolio Bilthoven, The Netherlands, 1 July 2020 – Bilthoven, The Netherlands based Intravacc, a worldwide leading translational research and development vaccine organization with an extensive track record in developing viral…

• iBoost technology well suited for developing cancer vaccines
• Joint development of Covid-19 vaccine using iBoost

Intranasal immunization with Intravacc’s experimental whooping cough vaccine confers broad protection Bilthoven, The Netherlands, 22 June 2020 – Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing viral and bacterial vaccines,…

• Need for improved whooping cough vaccines
• Outer membrane vesicles from Bordetella pertussis bacteria are potent immunogens
• Intranasal immunization shows both excellent systemic and immune responses
• Needle free immunization possible
• Data published in medical journal Scientific Reports

Intravacc and Versatope sign research service agreement to develop universal influenza vaccine based on OMV technology Bilthoven, The Netherlands, Lowell, Mass., USA, June 8 2020 – Intravacc, one of the leading translational research and development vaccine institutes with an extensive…

• Influenza vaccines were overall only 29% effective during the 2018–2019 influenza season
• High medical costs drive the need for finding a more universal influenza vaccine
• Intravacc’s OMV technology platform well suited to support the development of new pandemic response vaccines

Intravacc partners with Wageningen Bioveterinary Research and Utrecht University to develop an intranasal COVID-19 vaccine Bilthoven, Lelystad and Utrecht, The Netherlands, 4 June 2020 – Intravacc, one of the world’s leading translational research and development vaccine institutes, with an extensive…

• Development through a newly established public private partnership
• Vaccine consists of a Newcastle disease virus (NDV) vector, expressing the immunogenic spike (S) protein of SARS-CoV-2
• Intravacc to develop a scalable vaccine production process, using its FDA-approved Vero cell platform, in preparation of GMP productions

Intravacc to develop emergency and conventional COVID-19 vaccines Bilthoven, The Netherlands – 08.00 CET, May 14, 2020 – Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing viral and bacterial vaccines,…

• Vaccine concepts based on Intravacc’s platform technologies, proven safe in humans
• Emergency vaccine designed to activate cytotoxic T-cell responses
• Data are published in peer reviewed journal Vaccine

Intravacc appoints Dr Jan Groen as CEO Bilthoven, The Netherlands – 07.00 CRT, April 3, 2020 – Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record developing viral and bacterial vaccines from discovery…